Haleon plc: disposal of the ChapStick brand completed
31 May 2024: Haleon plc ("Haleon") has today announced that it has completed the disposal of the ChapStick brand to Suave Brands Company, a portfolio company of Yellow Wood Partners.
On 25 January 2024, Haleon announced that it had reached a binding agreement for the sale of the ChapStick brand to Suave Brands Company for pre-tax cash proceeds of approximately $430 million, as well as a passive minority interest in Suave Brands Company.
| Enquiries
|
| ||
| Investors | Media
| ||
| Sonya Ghobrial | +44 7392 784784 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel | +44 7552 484646 | Gemma Thomas | +44 7985 175048 |
| Emma White | +44 7823 523562 | | |
| Email: corporate.media@haleon.com | |||
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.